In a number of studies, selected biologically active substances were indicated as contributing to the etiology (IAPP [16,31,32,33,34,35,36], proIAPP [17,18,37], I-FABP [24]), course (CST [38,39], ChgA [40,41,42]) or the development of various complications (neuropathy—NGF [43,44,45], cardiovascular complications—PAF [26,46,47], and cardiovascular complications and nephropatia—UMOD [28,48,49]). Here, FABP2 is linked to neuropathy.